{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:50:37Z","timestamp":1789537837613,"version":"build-2803163510"},"reference-count":34,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.1080\/13543784.2021.1985462","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T10:55:25Z","timestamp":1633085725000},"page":"1017-1023","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension"],"prefix":"10.1080","volume":"30","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[{"name":"Metabolism Department, Centre De Recherche Des Cordeliers. Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Medicine, Comprehensive Hypertension Center, Chicago, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.2174\/187152506775268776"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-018-0158-6"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2014.04.008"},{"key":"cit0008","volume-title":"Prescribing information","author":"Aldactone","year":"2021"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283455ca5"},{"key":"cit0010","volume-title":"Prescribing information","author":"Inspra","year":"2018"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0649-2"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"cit0013","unstructured":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD); ClinicalTrials.gov identifier: NCT02545049. Bethesda (MD): National Library of Medicine (US). Updated 2 February 2021. Available at: [Last accessed 2021 Jul 19]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02545049"},{"key":"cit0014","unstructured":"FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes. FDA Press Release. Washington DC: FDA. Updated 9 July 2021. Available at: [Last accessed 2021 Jul 19]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01073-5"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60834-X"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065"},{"issue":"2","key":"cit0018","first-page":"1009","volume":"3","author":"Chow C","year":"2017","journal-title":"Journal of Drug Research and Development"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs061"},{"key":"cit0020","doi-asserted-by":"crossref","unstructured":"Bakris G, Pergola PE, and Delgado B, et al.Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension 2021:HYPERTENSIONAHA. 121.17073.","DOI":"10.1161\/HYPERTENSIONAHA.121.17073"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.657957"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000366"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13616"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.855"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.182"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.865"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12705"},{"key":"cit0030","first-page":"604928","volume":"12","author":"F ZJ J","journal-title":"Front Pharmacol"},{"key":"cit0031","unstructured":"CDC. Chronic kidney disease surveillance system\u2014United States. Prevalence of CKD in the general population: CKD stages among US adults, 1988\u20131994 vs. 1999\u20132006 vs. 2007\u20132014 vs. 2015\u20132016. [cited 2021 Jan 14]. Available from: https:\/\/nccd.cdc.gov\/ckd\/TopicHome\/PrevalenceIncidence.aspx"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313599"},{"key":"cit0033","first-page":"2016","volume-title":"Poster presented at American Society of Nephrology Kidney Week meeting","author":"B Tx Z","year":"2016"},{"key":"cit0034","unstructured":"Type B (EOP2) Meeting Briefing Document, IND 117743. KBP-5074 (Mineralocorticoid Receptor Antagonist). Indication: Treatment of uncontrolled hypertension in patients with Stage 3b\/4 chronic kidney disease. KBP Biosciences PTE. Ltd; 2021 Apr 9."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1985462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T16:41:26Z","timestamp":1635784886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1985462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"alternative-id":["10.1080\/13543784.2021.1985462"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1985462","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}